The presentation of new data at a major conference like ASH can generate investor interest and potentially drive up the stock price. The focus on BEAM-101 and ESCAPE technology, coupled with the projected growth of the Sickle Cell Disease market, suggests a positive outlook for Beam Therapeutics.